Document Detail


A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia.
MedLine Citation:
PMID:  15733519     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The diagnostic utility of 24-h oesophageal ambulatory pH monitoring in patients with functional dyspepsia has not been well established. AIMS: We performed a prospective study of oesophageal pH monitoring in patients with functional dyspepsia in order to assess whether a positive pH test might predict response to proton pump inhibitor therapy in a subset of functional dyspepsia patients. PATIENTS: Forty Helicobacter pylori-negative functional dyspepsia patients (35 males and 5 females, mean age (+/-S.E.M.) of 54+/-2.4 years) with predominantly unspecified dyspepsia subtype and normal distal oesophageal biopsies. METHODS: All subjects were randomised in a double-blind fashion to either omeprazole 20 mg/day or placebo daily for four weeks after 24-h pH monitoring. RESULTS: Twenty-four-hour pH monitoring was abnormal in 9 of the 21 patients (43%) in the omeprazole group and 5/19 (26%) of the placebo group (p=NS). Patients who reported symptomatic improvement on the Gastrointestinal Symptom Rating Scale were no more likely to have abnormal scores on pH monitoring than patients who did not have symptomatic response. CONCLUSIONS: Although approximately one-third of functional dyspepsia patients will have abnormal profiles on 24-h ambulatory oesophageal pH monitoring, an abnormal score does not appear to predict response to proton pump inhibitor therapy in patients with unspecified functional dyspepsia.
Authors:
L B Gerson; G Triadafilopoulos
Related Documents :
11467629 - The role of acid and duodenal gastroesophageal reflux in symptomatic gerd.
16700899 - Review article: acid-related disease--what are the unmet clinical needs?
7340349 - The use of oesophageal ph-monitoring for the evaluation of gastrooesophageal reflux aft...
12885989 - Abnormal oesophageal motility in patients with chronic cough.
15743349 - Dilated intercellular spaces of esophageal epithelium in nonerosive reflux disease pati...
11837739 - Symptom predictability of reflux-induced respiratory disease.
23548989 - Stereotactic radiosurgery for trigeminal schwannoma: a clinical retrospective study in ...
20811489 - Prevalence, detection, and management of the metabolic syndrome in patients with acute ...
7210659 - Bleeding after liver biopsy.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver     Volume:  37     ISSN:  1590-8658     ISO Abbreviation:  Dig Liver Dis     Publication Date:  2005 Feb 
Date Detail:
Created Date:  2005-02-28     Completed Date:  2005-06-28     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  100958385     Medline TA:  Dig Liver Dis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  87-91     Citation Subset:  IM    
Affiliation:
Division of Gastroenterology and Hepatology, A 149, Stanford University School of Medicine, Stanford University, Stanford, CA 94305-5202, USA. lgerson@stanford.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Ulcer Agents / therapeutic use
Double-Blind Method
Dyspepsia / drug therapy,  physiopathology*
Esophagus / physiopathology*
Female
Humans
Hydrogen-Ion Concentration
Male
Middle Aged
Monitoring, Ambulatory
Monitoring, Physiologic
Omeprazole / therapeutic use
Prospective Studies
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Ulcer Agents; 73590-58-6/Omeprazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hyponatremia in liver cirrhosis: pathophysiological principles of management.
Next Document:  Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.